Stock Yards Bank & Trust Co. Buys 651 Shares of Novo Nordisk A/S (NYSE:NVO)

Stock Yards Bank & Trust Co. grew its position in Novo Nordisk A/S (NYSE:NVO) by 16.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,604 shares of the company’s stock after acquiring an additional 651 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Novo Nordisk A/S were worth $396,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter valued at about $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Albion Financial Group UT boosted its position in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC grew its holdings in Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after acquiring an additional 243 shares during the last quarter. Finally, Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $48,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent research reports. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Down 2.1 %

Novo Nordisk A/S stock opened at $82.64 on Tuesday. The company has a market capitalization of $370.85 billion, a PE ratio of 26.74, a PEG ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The firm’s fifty day moving average is $93.56 and its 200 day moving average is $112.87. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.